FDA gives breakthrough therapy designation to experimental hepatitis C regimen

An experimental drug regimen under development by AbbVie could change the way hepatitis C is treated, according to a special designation it received from the Food and Drug Administration.

http://www.drugstorenews.com/article/fda-gives-breakthrough-therapy-designation-experimental-hepatitis-c-regimen